MétaCan
Menu
← Back to cohort
Record W4403841888 · doi:10.1681/asn.20242wv2xw41

Effects of Semaglutide on Kidney Parameters in Patients with Obesity and Nondiabetic CKD

2024· article· en· W4403841888 on OpenAlexaff
Hiddo Jan L. Heerspink, Ellen M. Apperloo, Niels Jongs, Secundino Cigarrán, María José Soler, Josep M. Cruzado, Annemarie B. van der Aart, Gozewijn D. Laverman, Jacobien C. Verhave, Sofia B. Ahmed, Roland E. Schmieder, Christoph Wanner, David Z.I. Cherney, José Luis Górriz

Bibliographic record

VenueJournal of the American Society of Nephrology · 2024
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsUniversity of TorontoUniversity of Alberta
Fundersnot available
KeywordsSemaglutideMedicineObesityInternal medicineKidney diseaseUrologyEndocrinologyDiabetes mellitusType 2 diabetes

Abstract

fetched live from OpenAlex

Background: Semaglutide is a glucagon like peptide 1 receptor agonist which reduces albuminuria and the risk of kidney failure in patients with type 2 diabetes and chronic kidney disease (CKD). We assessed the effects of semaglutide in patients with overweight/obesity and albuminuric CKD without diabetes. Methods: We conducted a multicenter randomized placebo-controlled clinical trial in adults with CKD (eGFR ≥25 mL/min/1.73m2, urine albumin-to-creatinine ratio [UACR] ≥30 and <3500 mg/g), body mass index ≥27 kg/m2 and HbA1c <6.5% without use of hypoglycemic agents. Participants were randomized to 24 weeks treatment with subcutaneous semaglutide 2.4 mg/week or placebo adjunctive to renin-angiotensin-system inhibition when indicated. The primary endpoint was percentage change from baseline in UACR at week 24. Secondary endpoints included change in iohexol measured GFR, estimated GFR, body weight, and systolic blood pressure (BP). Safety was monitored throughout. Results: Of 125 screened participants, 101 were randomized to semaglutide or placebo. Mean age was 55.8 (SD 12) years, 40 (39.6%) were female, median UACR was 251 mg/g (IQR 100, 584), eGFR 65.0 (SD 25) mL/min/1.73m2. Chronic glomerulonephritis (N=25) and hypertensive CKD (N=27) were the most common CKD etiologies. At week 24, the placebo-corrected geometric mean change from baseline in UACR with semaglutide was -52.1% (95%CI -65.2, -34.1; p<0.0001). Compared to placebo, mGFR was changed at week 24 with semaglutide by -1.9 mL/min/1.73m2 (95%CI -8.0, 4.3). Corresponding changes in eGFR-creatinine and eGFR-cystatin C were -1.1 (95%CI -4.8, 2.6) and +2.1 mL/min/1.73m2 (95%CI -1.7, 5.9), respectively. Semaglutide compared to placebo changed body weight by -9.1 kg (95%CI -11.1, -7.1) and systolic BP by -6.3 mmHg (95%CI -11.1, -1.5). Gastrointestinal adverse events were more often reported in the semaglutide (N=30) versus placebo group (N=15). Conclusion: Treatment with semaglutide for 24 weeks in patients with overweight/obesity and CKD without diabetes resulted in a robust and clinically meaningful reduction in UACR. These results support further trials to assess long-term efficacy and safety of semaglutide in these patients. Funding: Commercial Support - Novo Nordisk provided a grant to the University Medical Center Groningen to conduct this investigator initiated clinical trial

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.004
GPT teacher head0.220
Teacher spread0.216 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the American Society of Nephrology→Same topicDiabetes Treatment and Management→French-language works237,207→